Adult height in sixty girls with Turner syndrome treated with growth hormone matched with an untreated group

被引:27
|
作者
Pasquino, AM
Pucarelli, I
Segni, M
Tarani, L
Calcaterra, V
Larizza, D
机构
[1] Univ Roma La Sapienza, Dipartimento Pediat, I-00161 Rome, Italy
[2] Policlin San Matteo, IRCCS, I-27100 Pavia, Italy
[3] Univ Pavia, Dept Pediat Sci, I-27100 Pavia, Italy
关键词
D O I
10.1007/BF03347202
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The main clinical feature of Turner syndrome (TS) is growth failure, with a mean spontaneous adult height ranging between 136 and 147 cm, according to the specific curves of various populations. Though a classical deficiency of GH has not been generally demonstrated, GH has been administered since 1980 in trials, using replacement doses just initially, with a subsequent trend to increase it. We report the outcome of GH therapy given at the fixed dose of 0.33 mg/kg/week in 60 TS girls observed until adult height; 59 untreated TS girls, matched for auxological, karyotypical characteristics and time of observation, born within the same decade served as controls to evaluate GH efficacy. The calculation of the gain in cm over PAH was performed on specific Italian Turner curves, as well as height evaluation as SD score and growth velocity. The same calculations were made using Lyon references and Tanner standards. The mean CA at the beginning of GH treatment was 10.9 +/- 2.76 yr (range 4.5-15.9). Mean adult height of treated group was 151 +/- 6.1 cm with a gain over the PAH calculated at start of therapy (142.9 +/- 5.3 cm) of 8.2 +/- 3.9 cm. Ns change was observed be-tween the PAH at first observation (143.6 +/- 7.0 cm) and adult height (144.3 +/- 5.6 cm) in the control group. Treatment was well tolerated, no relevant side effects were observed, glucose metabolism resulted no more affected than in untreated subjects, IGF-I levels remained within 2 SD. Our results in 60 TS girls, though the dose remained unchanged throughout the treatment, show a good response, characterized by a striking variability in each patient (mean gain in cm over PAH at adult height of 8.17 +/- 3.9, range 3-21 cm), and significant also in comparison with the control group. As the chronological age at start of therapy ranged between 4.5 to 15.9 yr, the results were further evaluated dividing the patients into two groups, according to the age, < or > 11 yr. Thirty girls were < 11 yr (mean 8.7 +/- 1.76 yr) and 30 were > 11 yr (mean 13.2 +/- 1.4 yr). The gain in cm over the PAH in each group was, respectively, 8.1 +/- 3.4 and 8.2 +/- 4.3 cm without any significant difference between the two groups, showing no negative correlation between the CA at the beginning of GH and the response to treatment. (c) 2005, Editrice Kurtis.
引用
收藏
页码:350 / 356
页数:7
相关论文
共 50 条
  • [31] Effect of Oxandrolone on Glucose Metabolism in Growth Hormone-Treated Girls with Turner Syndrome
    Menke, Leonie A.
    Sas, Theo C. J.
    Stijnen, Theo
    Zandwijken, Gladys R. J.
    Keizer-Schrama, Sabine M. P. F. de Muinck
    Otten, Barto J.
    Wit, Jan M.
    HORMONE RESEARCH IN PAEDIATRICS, 2011, 75 (02): : 115 - 122
  • [32] The Effect of Oxandrolone on Voice Frequency in Growth Hormone-Treated Girls With Turner Syndrome
    Menke, Leonie A.
    Sas, Theo C. J.
    van Koningsbrugge, Sophie H. L.
    de Ridder, Maria A. J.
    Zandwijken, Gladys R. J.
    Boersma, Bart
    Dejonckere, Philippe H.
    Keizer-Schrama, Sabine M. P. F. de Muinck
    Otten, Barto J.
    Wit, Jan M.
    JOURNAL OF VOICE, 2011, 25 (05) : 602 - 610
  • [33] Growth hormone treatment regimens in girls with Turner syndrome
    Keizer-Schrama, SMPFD
    Sas, TCJ
    ACTA PAEDIATRICA, 1999, 88 : 126 - 129
  • [34] ADULT HEIGHT IS IMPROVED WITH GROWTH-HORMONE THERAPY WITH OR WITHOUT OXANDROLONE IN TURNER SYNDROME
    ROSENFELD, RG
    ATTIE, KM
    JOHANSON, AJ
    PEDIATRIC RESEARCH, 1991, 29 (04) : A85 - A85
  • [35] Does growth-hormone supplementation affect adult height in Turner's syndrome?
    Taback, SP
    Collu, R
    Deal, CL
    Guyda, HJ
    Salisbury, S
    Dean, HJ
    VanVliet, G
    LANCET, 1996, 348 (9019): : 25 - 27
  • [36] Components of the metabolic syndrome in girls with Turner syndrome treated with growth hormone in a long term prospective study
    Blaszczyk, Ewa
    Shulhai, Anna-Mariia
    Gieburowska, Joanna
    Baranski, Kamil
    Gawlik, Aneta Monika
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [37] Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone
    Pasquino, AM
    Pucarelli, I
    Roggini, M
    Segni, M
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (02): : 619 - 622
  • [38] Experience With 68 Girls With Turner's Syndrome and Evaluation of Final Height in 26 Patients Treated With Growth Hormone in Combination or Without Oxandrolone
    Moayeri, H.
    Hakimi, Amir G. H.
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2005, 3 (04) : 193 - 198
  • [39] TREATMENT WITH 2 GROWTH-HORMONE REGIMENS IN GIRLS WITH TURNER-SYNDROME - FINAL HEIGHT RESULTS
    MASSA, G
    OTTEN, BJ
    KEIZERSCHRAMA, SMPDM
    DELEMARREVANDEWAAL, HA
    JANSEN, M
    VULSMA, T
    OOSTDIJK, W
    WAELKENS, JJ
    WIT, JM
    HORMONE RESEARCH, 1995, 43 (04) : 144 - 146
  • [40] Variable effect of growth hormone on growth and final adult height in Scottish patients with Turner's syndrome
    Chu, CE
    Paterson, WF
    Kelnar, CJH
    Smail, PJ
    Greene, SA
    Donaldson, MDC
    ACTA PAEDIATRICA, 1997, 86 (02) : 160 - 164